Evidence map›Paper›PMID 35177423›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022

Wenyu Wu, Fei Yu, Pengjun Zhang, Ting Bu, Jingjing Fu, Shuyue Ai, Qinqin You, Liang Shi, Guoqiang Shao, Feng Wang and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. First-in-human evaluation of [Annals of medicine · 2026
    Article
  2. Article
  3. Article
  4. Neurotensin and Its Involvement in Female Hormone-Sensitive Cancers.International journal of molecular sciences · 2024
    Review
  5. Recent Progress in Synthesis ofNuclear medicine and molecular imaging · 2024
    Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Wenyu WuDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Fei YuDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Pengjun ZhangDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Ting BuDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Jingjing FuDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Shuyue AiDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Qinqin YouDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Liang ShiDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Guoqiang ShaoDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Feng WangDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China; fengwangcn@hotmail.com marina.hodolic@gmail.com.
Marina HodolicNuclear Medicine Research Department, IASON, Graz, Austria; fengwangcn@hotmail.com marina.hodolic@gmail.com.
Hongqian GuoDepartment of Urology, Drum Tower Hospital, Medical School of Nanjing University, Nanjing University, Nanjing, China.
Nanjing Medical University · CNNanjing Drum Tower Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate-specific membrane antigen (PSMA)-negative neuroendocrine prostate cancer (PCa) is a subtype of PCa likely to be lethal, with limited clinical diagnostic and therapeutic options. High expression of neurotensin receptor subtype 1 (NTR1) is associated with neuroendocrine differentiation of PCa, which makes NTR1 a potential target for neuroendocrine PCa. In this study, the NTR1-targeted tracer

Indexed as

Gallium RadioisotopesProstatic NeoplasmsAndrogensAnimalsCell Line, TumorGallium IsotopesHeterocyclic Compounds, 1-RingHumansMaleNeurotensinPositron-Emission TomographyPositron Emission Tomography Computed TomographyRadiopharmaceuticalsReceptors, NeurotensinTissue Distribution1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidAndrogensgallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesHeterocyclic Compounds, 1-RingNeurotensinRadiopharmaceuticalsReceptors, Neurotensin68Ga-DOTA-NT-20.3neuroendocrine differentiationneurotensin receptor subtype 1PETprostate cancer

Identifiers

PMID35177423
PMCPMC9454456
OpenAlexW4213241853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.